Medicare announced on August 2nd the conditions under which Medicare will be provide coverage for autologous blood-derived products for the treatment of chronic wounds.
CMS issued the National Coverage Determination: Decision Memorandum for CAG-00190R3 – Autologous Blood-Derived Products for Chronic Non-Healing Wounds. Link provided below.
CMS will cover autologous platelet-rich plasma (PRP) only for patients who have chronic non-healing diabetic, pressure, and/or venous wounds and when all the following conditions are met:
- The patient is enrolled in a clinical research study that addresses the specific questions using validated and reliable methods of evaluation.
- Clinical study applications for coverage pursuant to this National Coverage Determination (NCD) must be received by August 2, 2014.
- The clinical research study meets specific requirements identified in the Decision Memo.